Once bound to CCR4, mogamulizumab exerts potent antitumor effects through ADCC, inducing cell-mediated lysis and depletion of CCR4-expressing malignant T cells and Tregs (107).The therapeutic efficacy of Mogamulizumab on adult T-cell leukemia and cutaneous T-cell lymphoma is also considered to be partly due to depletion of immunosuppressive Tregs (108, 109). Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.